September 27th 2023
Based on findings from the phase 1/2 BCHILD trial, the FDA approved bosutinib for pediatric chronic myelogenous leukemia.
September 10th 2023
Asciminib may be more tolerable than bosutinib in the treatment of those with chronic myeloid leukemia, according to Michael Deininger, MD.
September 8th 2023
A major molecular response at 3 months appears to increase the probability of overall survival in patients treated with ponatinib for chronic-phase chronic myeloid leukemia in the phase 2 PACE trial.
May 23rd 2023
Asciminib does not appear to interfere with the general life activities of patients with resistant/intolerant chronic phase chronic myeloid leukemia in the phase 3 ASCEMBL trial.
April 5th 2023
A panel of experts from Moffitt and Mayo discuss newly published data from the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition.
Cross Q&A: Role of Olverembatinib in Heavily Pretreated CML
In this cross Q&A, both the Mayo Clinic and UT Southwestern teams share insight on the role of olverembatinib in relapsed/refractory chronic myeloid leukemia.
Olverembatinib Study in Patients With Heavily Pretreated Chronic Myeloid Leukemia
A comprehensive review of chronic myeloid leukemia olverembatinib data led by expert Kebede Begna, MD, from the Mayo Clinic team.
Cross Q&A: Arterial Occlusive Events With Ponatinib in the PACE Trial
Following a review of the retrospective analysis of PACE, experts reflect on its importance in understanding the risk of arterial occlusive events with ponatinib.
Chronic Myeloid Leukemia: Retrospective Analysis of the PACE Study
A focused discussion led by expert Abhishek Mangaonkar, MBBS, on a retrospective analysis elucidating arterial occlusive events within the PACE study.
Cross Q&A: Ponatinib Dosing in Relapsed/Refractory Chronic-Phase CML
Expert perspectives from the Mayo Clinic and UT Southwestern teams on applications of the OPTIC study and optimal ponatinib dosing in chronic myeloid leukemia.
Chronic-Phase CML: The OPTIC Study
Key opinion leader Kebede Begna, MD, reviews data from the OPTIC study focused on ponatinib dosing in chronic-phase CML.
Team Introductions: CML Experts From UT Southwestern vs. Mayo Clinic
Expert panelists from UT Southwestern and the Mayo Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent clinical trial data in chronic myeloid leukemia.
Ongoing Studies in CML-CP Offer Hope to Future Treatments
Talha Badar, MBBS, MD, discussed ongoing trials in the treatment of chronic myeloid leukemia in chronic phase, as well as his hope for future therapies in the space.
Asciminib Offers Additional Tool to Treat CML-CP
Talha Badar, MBBS, MD, discussed how results from the phase 3 ASCEMBL study of asciminib will impact clinical practice in treating chronic myeloid leukemia in chronic phase.
Superiority of Asciminib in CML-CP Is a ‘Win-Win’ for Patients
Talha Badar, MBBS, MD, discussed the unmet needs in the treatment of chronic myeloid leukemia in chronic phase.
Phase 3 ASCEMBL Study Demonstrates Superiority of Asciminib in CML-CP
Talha Badar, MBBS, MD, discussed the results of the phase 3 ASCEMBL trial, demonstrating the superiority of asciminib versus bosutinib in patients with chronic myeloid leukemia in chronic phase.
Highlighting Ongoing Clinical Trials in CML From ASH
Kendra Sweet, MD, discussed several ongoing studies in chronic myeloid leukemia, with some initial results presented at the 2022 American Society of Hematology Annual Meeting and Exposition.
The Implications of CML Data From ASH, And Important Takeaways for Providers
Kendra Sweet, MD, examined how the data surrounding asciminib in chronic myeloid leukemia will affect the standard of care treatment options.
How Ponatinib Factors into the Treatment of a Type of Leukemia
Kendra Sweet, MD, discussed results of the the phase 2 OPTIC trial, which investigated ponatinib in a group of patients with resistant, chronic phase chronic myeloid leukemia.
Efficacy Produced from Olverembatinib in Ponatinib-Resistant, T25I-Mutant CML, and Ph-Positive ALL
Those with chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia, and those with CML whose tumors have a T315I mutation, were found to have improved efficacy when olverembatinib was given.
Acceptable Clinical Benefit Rate With Olverembatinib in BCR-ABL1 Anti-TKI CML
Patients with BCR-ABL1 T315I-mutant chronic myeloid leukemia, chronic phase, or acute phase who are resistant to tyrosine kinase inhibitors were found to show a clinical benefit with olvermbatinib.
Recap: MSKCC and Dana-Farber 'Face Off' With a Debate Over Outcomes in CML
Two teams from leading institutions go head-to-head to debate the latest datasets and advances in chronic myeloid leukemia (CML).
Cross Q&A: Team Dana-Farber
The Memorial Sloan Kettering team gets their chance to question the Dana-Farber team on the datasets they presented.
Ponatinib after TKI Failure in Chronic Myeloid Leukemia
Dr DeAngelo shares data on the use of ponatinib for CML treatment after failure of second-generation TKIs.
Asciminib vs Bosutinib in Chronic Myeloid Leukemia Treatment
Daniel DeAngelo, MD, PhD, presents data from a phase 3 study comparing asciminib and bosutinib after treatment with 2 or more prior TKIs in CML.
Cross Q&A: Team Memorial Sloan Kettering
The Dana-Farber team puts Memorial Sloan Kettering to the test and questions the panel on the presented abstracts.
Chronic Myeloid Leukemia: Arterial Occlusive Events in the PACE Trial
Dr Michael Mauro continues his presentation with a look at an analysis of the arterial occlusive events in the PACE trial in CML.
The OPTIC Trial: A Ponatinib Dose-Ranging Study in Chronic Myeloid Leukemia
Michael Mauro, MD, presents data on a phase 2 ponatinib dose-ranging study in chronic-phase CML.
Team Introductions: Memorial Sloan Kettering “Yankees” vs Dana-Farber “Red Sox”
Steven Frommeyer introduces the two teams of competing physicians participating in Cancer Network® Face-off.
European Commission Approves Asciminib in Philadelphia Chromosome–Positive CML
Results from the phase 3 ASCEMBL trial led to the approval of asciminib by the European Commission for patients with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.
Asciminib Yields Long-Lasting MMRs in Previously Treated CML-CP
Findings from the phase 3 ASCEMBL trial indicated that asciminib as a treatment for chronic myelogenous leukemia in chronic phase could represent a new standard of care.
Patients With Chronic-Phase CML Achieved Deeper, More Durable Molecular Responses With Asciminib Vs Bosutinib
Improvement in major molecular response rate and depth of response coupled with a favorable safety profile were noted with asciminib vs bosutinib in patients with chronic-phase chronic myeloid leukemia.
Promising Activity Observed With Ponatinib Treatment in T315I-Mutated CP-CML
In a population of patients with chronic myeloid leukemia with resistant disease experienced promising activity following treatment with ponatinib regardless of T315I mutation status.
Asciminib Granted Accelerated Approval by FDA for Ph+ Chronic Myeloid Leukemia in 2 Indications
The FDA granted accelerated approval to asciminib for the treatment of patients with Philadelphia chromosome–positive chronic myeloid leukemia for 2 indications.
FDA Grants Breakthrough Therapy Designation to Asciminib for 2 CML Indications
The FDA has granted breakthrough therapy designation to asciminib for the treatment of adult patients with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase who have been previously treated with 2 or more tyrosine kinase inhibitors; or who harbor the T315I mutation.
2 Clarke Drive Cranbury, NJ 08512